Cytogenetics and molecular genetics of lung cancer.
The development and progression of lung cancer is a multistep process characterized by the accumulation of numerous genetic and epigenetic alterations, some of which occur early in the course of disease. In this review, we summarize cytogenetic imbalances and molecular genetic/epigenetic changes seen in human small-cell and non-small-cell lung cancer. Alterations of tumor suppressor genes and oncogenes leading to perturbations of key cell-regulatory and growth-control pathways are highlighted. The translational implications of molecular biomarkers for risk assessment, early detection, and monitoring of chemoprevention trials are discussed.
Mitsuuchi
Yasuhiro
Y
Fox Chase Cancer Center in Philadelphia, Pennsylvania 19111, USA.
Testa
Joseph R
JR
D017766:Acid Anhydride Hydrolases; D002893:Chromosomes, Human, Pair 3; D003582:Cytogenetics; D020868:Gene Silencing; D019942:Genes, p16; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics*; D009363:Neoplasm Proteins / Q000235:genetics; D016271:Proto-Oncogene Proteins c-myc / Q000235:genetics / Q000378:metabolism; D016160:Retinoblastoma Protein / Q000235:genetics; D017384:Sequence Deletion; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism; D018631:ras Proteins / Q000235:genetics / Q000378:metabolism; D000099170:Bis(5'-adenosyl)triphosphatase
D017766:Acid Anhydride Hydrolases; D009363:Neoplasm Proteins; D016271:Proto-Oncogene Proteins c-myc; D016160:Retinoblastoma Protein; D016159:Tumor Suppressor Protein p53; D018631:ras Proteins; D000099170:Bis(5'-adenosyl)triphosphatase